Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

Stopped early · Phase 1

Conditions studied: Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia

In brief

This pilot clinical trial studies infusion of expanded cord blood hematopoietic progenitor cells following combination chemotherapy in treating younger patients with acute myeloid leukemia that has relapsed or has not responded to treatment. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemotherapy also kills healthy infection-fighting cells, increasing the risk of infection. The infusion of expanded cord blood hematopoietic progenitor cells may be able to replace blood-forming cells that were destroyed by chemotherapy. This cellular therapy may decrease the risk of infection following chemotherapy.

Key facts

Study ID: NCT01701323
Run by: Nohla Therapeutics, Inc.
People needed: 7
Starts: 2012-12-10
Expected to finish: 2018-05-10
Last updated by the study team: 2019-03-01

Who can join

Age: 1 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients must have a diagnosis of AML or acute leukemia of ambiguous lineage according to World Health Organization (WHO) classification with >= 5% of disease in bone marrow (BM)
Recipients of prior allogeneic hematopoietic stem cell transplantation for AML or acute leukemia of ambiguous lineage are eligible if they do not have graft-versus-host disease (GVHD) or they have quiescent GVHD whether or not they are receiving immunosuppressive therapy
Must have a Lansky or Karnofsky performance status of >= 50; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age
Patients must have recovered from the acute toxicity of all prior chemotherapy
The following amounts of time must have elapsed prior to entry on study:
2 weeks from local radiation therapy (XRT)
8 weeks from prior craniospinal or if > 50% of the pelvis has been irradiated
6 weeks must have elapsed if other bone marrow radiation has occurred
Adequate cardiac, renal, pulmonary, and hepatic function
Patient must have a life expectancy of at least 2 months
Females of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
Females of childbearing potential and males should agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation

You may not qualify if…

Recipients of prior allogeneic hematopoietic stem cell transplant (HSCT) with active acute or chronic GVHD
Patients with history of Down's syndrome, Fanconi anemia or other known marrow failure condition
Patients currently receiving other investigational drugs are not eligible
Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol with the exception of intrathecal chemotherapy; this includes the tyrosine kinase inhibitor sorafenib which must not be initiated until patient demonstrates count recovery
Patients with a systemic fungal, bacterial, viral, or other infection not controlled despite appropriate antibiotics or other treatment; uncontrolled systemic infections require infectious disease consultation for verification
Patients who are platelet refractory prior to initiation of protocol therapy
Pregnant or lactating patients
Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results

Where it is running

Emory University/Winship Cancer Institute — Atlanta, Georgia, United States
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.